(Q24245518)

https://api.crossref.org/works/10.1002%2F14651858.CD002030.PUB2

Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002030.PUB2

Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy an

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002030.PUB2

Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002030.PUB2

Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002030.PUB2

Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002030.PUB2

Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment--TAP and VIP report No. 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002030.PUB2

7 January 2021

Natural history of minimally classic subfoveal choroidal neovascular lesions in the treatment of age-related macular degeneration with photodynamic therapy (TAP) investigation: outcomes potentially relevant to management--TAP report No. 6.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002030.PUB2

7 January 2021

Large submacular hemorrhages after verteporfin therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002030.PUB2

7 January 2021

Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP and VIP report no. 3.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002030.PUB2

7 January 2021

Effects of verteporfin therapy on central visual field function

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002030.PUB2

7 January 2021

Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynami

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002030.PUB2

7 January 2021

Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002030.PUB2

7 January 2021

Verteporfin infusion-associated pain

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002030.PUB2

7 January 2021

Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002030.PUB2

7 January 2021

Agreement among ophthalmologists in evaluating fluorescein angiograms in patients with neovascular age-related macular degeneration for photodynamic therapy eligibility (FLAP-study).

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002030.PUB2

7 January 2021

Changes in confocal indocyanine green angiography through two years after photodynamic therapy with verteporfin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002030.PUB2

7 January 2021

Photodynamic therapy for choroidal neovascularization: a review.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002030.PUB2

7 January 2021

Effects of verteporfin therapy on contrast on sensitivity: Results From the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) investigation-TAP report No 4.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002030.PUB2

7 January 2021

Verteporfin therapy in age-related macular degeneration (VAM): an open-label multicenter photodynamic therapy study of 4,435 patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002030.PUB2

7 January 2021

Photodynamic therapy with verteporfin is effective, but how big is its effect? Results of a systematic review

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002030.PUB2

7 January 2021

A prospective study of visual function and quality of life following PDT in patients with wet age related macular degeneration

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002030.PUB2

7 January 2021

Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002030.PUB2

7 January 2021